ArticleACS nano2016
Pretargeted Positron Emission Tomography Imaging That Employs Supramolecular Nanoparticles with in Vivo Bioorthogonal Chemistry.
Article in ACS nano, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Supramolecular Materials and Strategies for Bioorthogonal Chemical Transformations.Chemical reviews · 2025Review
- Article
- Current advance of nanotechnology in diagnosis and treatment for malignant tumors.Signal transduction and targeted therapy · 2024Review
- [RSC chemical biology · 2024Article
- Trans-cyclooctene-a Swiss army knife for bioorthogonal chemistry: exploring the synthesis, reactivity, and applications in biomedical breakthroughs.EJNMMI radiopharmacy and chemistry · 2024Review
- Exploring the Potential of Nanogels: From Drug Carriers to Radiopharmaceutical Agents.Advanced healthcare materials · 2024Review
- Click Chemistry and Radiochemistry: An Update.Bioconjugate chemistry · 2023Review
- Cooperative Capture Synthesis of Functionalized Heterorotaxanes─Chemical Scope, Kinetics, and Mechanistic Studies.Journal of the American Chemical Society · 2023Article
- Asymmetric rotaxanes as dual-modality supramolecular imaging agents for targeting cancer biomarkers.Communications chemistry · 2023Article
- New opportunities for RGD-engineered metal nanoparticles in cancer.Molecular cancer · 2023Review
- Recent Development of Rhenium-Based Materials in the Application of Diagnosis and Tumor Therapy.Molecules (Basel, Switzerland) · 2023Review
- Medical Imaging Technology and Imaging Agents.Advances in experimental medicine and biology · 2023Article
- Supramolecular Rotaxane-Based Multi-Modal Probes for Cancer Biomarker Imaging.Angewandte Chemie (International ed. in English) · 2022Article
- Recent Advances in the Development of Tetrazine Ligation Tools for Pretargeted Nuclear Imaging.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Insights into Elution of Anion Exchange Cartridges: Opening the Path toward AliphaticACS pharmacology & translational science · 2021Article
- Functionalized Particles Designed for Targeted Delivery.Polymers · 2021Review
- Nanoparticles and bioorthogonal chemistry joining forces for improved biomedical applications.Nanoscale advances · 2021Review
- Cyclodextrin-Based Contrast Agents for Medical Imaging.Molecules (Basel, Switzerland) · 2020Review
- Mesoporous Silica Nanoparticles as Theranostic Antitumoral Nanomedicines.Pharmaceutics · 2020Review
- Small Molecule Sensors Targeting the Bacterial Cell Wall.ACS infectious diseases · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
A pretargeted oncologic positron emission tomography (PET) imaging that leverages the power of supramolecular nanoparticles with in vivo bioorthogonal chemistry was demonstrated for the clinically relevant problem of tumor imaging. The advantages of this approach are that (i) the pharmacokinetics (PKs) of tumor-targeting and imaging agents can be independently altered via chemical alteration to achieve the desired in vivo performance and (ii) the interplay between the two PKs and other controllable variables confers a second layer of control toward improved PET imaging. In brief, we utilized supramolecular chemistry to synthesize tumor-targeting nanoparticles containing transcyclooctene (TCO, a bioorthogonal reactive motif), called TCO⊂SNPs. After the intravenous injection and subsequent concentration of the TCO⊂SNPs in the tumors of living mice, a small molecule containing both the complementary bioorthogonal motif (tetrazine, Tz) and a positron-emitting radioisotope ((64)Cu) was injected to react selectively and irreversibly to TCO. High-contrast PET imaging of the tumor mass was accomplished after the rapid clearance of the unreacted (64)Cu-Tz probe. Our nanoparticle approach encompasses a wider gamut of tumor types due to the use of EPR effects, which is a universal phenomenon for most solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.